OSEBX1,423.56+0.84%
EQNR284.60+4.20%
DNB198.35-1.15%
MOWI172.80+0.45%
Brent$71.24-0.32%
EUR/USD1.0824-0.14%
DXY104.18+0.08%
INDICATIVE · SAMPLE DATA
419540$877.0057

Bistos Co Ltd

Advanced Medical Equipment & TechnologyVerified

Bistos Co Ltd has a market price of 877 KRW per share, with a market capitalization of 19.64 billion KRW. The company's price-to-book ratio is 1.1, and its price-to-tangible-book ratio is also 1.1, indicating a valuation in line with tangible asset value. The enterprise value to EBITDA ratio is negative at -18.14, reflecting the company's current operating losses. The enterprise value to revenue ratio is 1.16, suggesting a modest revenue-based valuation. The company's profitability metrics are weak, with a return on equity of -3.9% and a return on assets of -3.38%. These figures are below the industry median for Advanced Medical Equipment & Technology, which typically shows positive returns. The company's operating income is negative at -1.096 billion KRW, and its net income is also negative at -699.12 million KRW, indicating a lack of profitability. Bistos Co Ltd's revenue is concentrated in disclosed segments, though specific geographic breakdowns are not provided in the input data. The company's exposure to geographic markets is not quantified, but its operations are based in Korea, which may limit diversification. The company's capital structure is relatively conservative, with a debt-to-equity ratio of 0.01, and a current ratio of 5.34, indicating strong short-term liquidity. The company's growth trajectory is uncertain, with no specific revenue growth projections provided in the input data. Historical revenue data shows a revenue of 17.1 billion KRW, but without prior periods, it is difficult to assess year-over-year performance. The company's operating cash flow is negative at -2.168 billion KRW, and its free cash flow is also negative at -427.27 million KRW, indicating cash flow challenges. The company's risk profile includes a medium liquidity risk, with a key flag indicating that net cash is negative after subtracting total debt. The dilution risk is assessed as low, with no immediate pressure for share issuance. The company's capital expenditures are negative at -188.06 million KRW, suggesting a reduction in investment in physical assets. Recent events and filings are not detailed in the input data, but the company's financial performance and cash flow position suggest a need for operational improvements. The company's negative operating and net income, combined with negative cash flows, indicate a need for strategic adjustments to achieve profitability.

30-day price · 419540+70.00 (+8.7%)
Low$796.00High$939.00Close$877.00As of25 May, 00:00 UTC
Profile
CompanyBistos Co Ltd
Ticker419540.KQ
SectorHealthcare
BusinessHealthcare Services & Equipment
Industry groupHealthcare Services & Equipment
IndustryAdvanced Medical Equipment & Technology
AI analysis

Business. Bistos Co Ltd is a Korea-based company engaged in the researching, developing, and manufacturing of medical equipment, including fetal monitors, patient monitors, infant incubators, and phototherapy devices.

Classification. Bistos Co Ltd is classified under the Healthcare sector, specifically in the Advanced Medical Equipment & Technology industry, with a confidence level of 0.92.

Bistos Co Ltd has a market price of 877 KRW per share, with a market capitalization of 19.64 billion KRW. The company's price-to-book ratio is 1.1, and its price-to-tangible-book ratio is also 1.1, indicating a valuation in line with tangible asset value. The enterprise value to EBITDA ratio is negative at -18.14, reflecting the company's current operating losses. The enterprise value to revenue ratio is 1.16, suggesting a modest revenue-based valuation. The company's profitability metrics are weak, with a return on equity of -3.9% and a return on assets of -3.38%. These figures are below the industry median for Advanced Medical Equipment & Technology, which typically shows positive returns. The company's operating income is negative at -1.096 billion KRW, and its net income is also negative at -699.12 million KRW, indicating a lack of profitability. Bistos Co Ltd's revenue is concentrated in disclosed segments, though specific geographic breakdowns are not provided in the input data. The company's exposure to geographic markets is not quantified, but its operations are based in Korea, which may limit diversification. The company's capital structure is relatively conservative, with a debt-to-equity ratio of 0.01, and a current ratio of 5.34, indicating strong short-term liquidity. The company's growth trajectory is uncertain, with no specific revenue growth projections provided in the input data. Historical revenue data shows a revenue of 17.1 billion KRW, but without prior periods, it is difficult to assess year-over-year performance. The company's operating cash flow is negative at -2.168 billion KRW, and its free cash flow is also negative at -427.27 million KRW, indicating cash flow challenges. The company's risk profile includes a medium liquidity risk, with a key flag indicating that net cash is negative after subtracting total debt. The dilution risk is assessed as low, with no immediate pressure for share issuance. The company's capital expenditures are negative at -188.06 million KRW, suggesting a reduction in investment in physical assets. Recent events and filings are not detailed in the input data, but the company's financial performance and cash flow position suggest a need for operational improvements. The company's negative operating and net income, combined with negative cash flows, indicate a need for strategic adjustments to achieve profitability.
Key takeaways
  • Bistos Co Ltd is currently unprofitable, with negative operating and net income.
  • The company's valuation is modest, with a price-to-book ratio of 1.1 and a negative EV/EBITDA ratio.
  • Liquidity is strong, with a current ratio of 5.34, but cash flow is negative.
  • The company's debt-to-equity ratio is low at 0.01, indicating a conservative capital structure.
  • Growth prospects are unclear due to the lack of forward-looking revenue projections.
  • --
  • ## RATIONALES
  • ```json
Financial snapshot
PeriodHA-latest
CurrencyKRW
Revenue$17.10B
Gross profit$4.28B
Operating income-$1.10B
Net income-$699.1M
R&D
SG&A
D&A
SBC
Operating cash flow-$2.17B
CapEx-$188.1M
Free cash flow-$427.3M
Total assets$20.71B
Total liabilities$2.80B
Total equity$17.91B
Cash & equivalents
Long-term debt$236.5M
Annual history (last 5)
PeriodRevenueOp IncomeNet IncomeFCF
FY0
FY-1
FY-2
FY-3
FY-4
PeriodGross %Op %Net %FCF %
FY0
FY-1
FY-2
FY-3
FY-4
PeriodAssetsEquityCashDebt
FY0
FY-1
FY-2
FY-3
FY-4
PeriodOCFCapExFCFSBC
FY0
FY-1
FY-2
FY-3
FY-4
Quarterly history (last 4)
PeriodRevenueOp IncomeNet IncomeFCF
FQ0
FQ-1
FQ-2
FQ-3
FQ-4
FQ-5
FQ-6
FQ-7
PeriodGross %Op %Net %FCF %
FQ0
FQ-1
FQ-2
FQ-3
FQ-4
FQ-5
FQ-6
FQ-7
PeriodAssetsEquityCashDebt
FQ0
FQ-1
FQ-2
FQ-3
FQ-4
FQ-5
FQ-6
FQ-7
PeriodOCFCapExFCFSBC
FQ0
FQ-1
FQ-2
FQ-3
FQ-4
FQ-5
FQ-6
FQ-7
Valuation
Market price$877.00
Market cap$19.64B
Enterprise value$19.88B
P/E
Reported non-GAAP P/E
EV/Revenue1.2
EV/Op income
EV/OCF
P/B1.1
P/Tangible book1.1
Tangible book$17.91B
Net cash-$236.5M
Current ratio5.3
Debt/Equity0.0
ROA-3.4%
ROE-3.9%
Cash conversion3.1%
CapEx/Revenue-1.1%
SBC/Revenue
Asset intensity
Dilution ratio0.0%
Risk assessment
Dilution riskLow
Liquidity riskMedium
  • Net cash is negative after subtracting total debt.
Industry benchmarks
Activity: Advanced Medical Equipment & Technology · cohort 3 companies
Metric419540Activity
Op margin-6.4%19.4% medp25 17.8% · p75 22.0%bottom quartile
Net margin-4.1%17.7% medp25 16.4% · p75 19.0%bottom quartile
Gross margin25.0%73.5% medp25 71.3% · p75 75.8%bottom quartile
R&D / revenue6.2% medp25 4.7% · p75 12.0%
CapEx / revenue-1.1%4.3% medp25 3.9% · p75 4.3%bottom quartile
Debt / equity1.0%41.5% medp25 29.2% · p75 51.3%bottom quartile
Source data
Underlying data the analysis-pipeline pulls and audits. Fetch timestamps + content hashes show when each source was last refreshed.
Company fundamentalsperiod FQ-7 · history via verified-market-data
no public URL
2026-05-04 22:21 UTC#a390cf01
Market quoteclose KRW 877.00 · shares 0.02B diluted
no public URL
2026-05-04 22:21 UTC#a07db728
Source: analysis-pipeline (hybrid)Generated: 2026-05-04 22:22 UTCJob: f66241c5